Fintel reports that on November 7, 2025, Wedbush maintained coverage of Maze Therapeutics (NasdaqGM:MAZE) with a Outperform recommendation.
Analyst Price Forecast Suggests 35.71% Upside
As of October 30, 2025, the average one-year price target for Maze Therapeutics is $38.76/share. The forecasts range from a low of $34.34 to a high of $52.50. The average price target represents an increase of 35.71% from its latest reported closing price of $28.56 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.59.
What is the Fund Sentiment?
There are 158 funds or institutions reporting positions in Maze Therapeutics. This is an increase of 13 owner(s) or 8.97% in the last quarter. Average portfolio weight of all funds dedicated to MAZE is 0.85%, an increase of 20.96%. Total shares owned by institutions decreased in the last three months by 3.31% to 39,487K shares. 
The put/call ratio of MAZE is 2.64, indicating a bearish outlook.
What are Other Shareholders Doing?
Trv Gp Iv holds 6,074K shares representing 13.85% ownership of the company. No change in the last quarter.
Frazier Life Sciences Management holds 4,567K shares representing 10.42% ownership of the company. In its prior filing, the firm reported owning 4,129K shares , representing an increase of 9.60%. The firm increased its portfolio allocation in MAZE by 7.85% over the last quarter.
Arch Venture holds 4,120K shares representing 9.40% ownership of the company. No change in the last quarter.
Deep Track Capital holds 3,949K shares representing 9.01% ownership of the company. In its prior filing, the firm reported owning 3,269K shares , representing an increase of 17.21%. The firm increased its portfolio allocation in MAZE by 33.32% over the last quarter.
Matrix Capital Management Company holds 2,486K shares representing 5.67% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
